参麦开肺散治疗系统性硬化症肺间质病变30例临床研究  

Clinical study on the treatment of pulmonary interstitial lesions in patients with systemic sclerosis by Shenmaikaifei powders

作　　者：郭刚[1] 李小佼[2] 李慧云[1] 张海顺[1] 钟起诚[1] 

机构地区：[1]河北医科大学附属以岭医院风湿免疫科,石家庄050091 [2]河北医科大学附属以岭医院影像科,石家庄050091

出　　处：《疑难病杂志》2015年第11期1137-1140,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金面上项目(No.81270120);河北省中医药管理局科研计划项目(No.2007140)

摘　　要：目的观察参麦开肺散治疗系统性硬化症肺间质病变的临床疗效。方法 2010年3月—2014年3月收治系统性硬化症肺间质病变患者65例,随机分为治疗组和对照组,治疗组33例,对照组32例。2组均给予基础常规治疗,治疗组另给予参麦开肺散,对照纰另给予罗红霉索、乙酰半胱氨酸泡腾片。12周为1个疗程。1个疗程后观察2组疗效,并检测2组治疗前后中医证候积分,6分钟步行距离(6MWT)、HRCT观察肺内磨玻璃样病变情况,肺功能[用力肺活量(FVC)、第1秒用力呼气容积(FEV_1)、FEV_1/FVC]改善情况。结果 2组实际完成试验各30例,治疗组总有效率为93.33%(28/30)岛于对照组的70.00%(21/30),差异有统计学意义(X^2=5.455,P<0.05)。与治疗前比较,2组治疗后中医证候积分、6MWT、HRCT观察肺内磨玻璃样病变情况,肺功能改善均改善(P<0.01或P<0.05),且治疗组气短、咳嗽等中医证候积分及肺功能改善优于对照组,差异均有统计学意义(P<0.01或P<0.05)。结论参麦开肺散治疗系统性硬化症肺问质病变疗效确切。Objective To observe the clinical effect of Shenmaikaifei powders for the treatment of pulmonary interstitial lesions in patients with systemic sclerosis.Methods From March 2010 to March 2014,65 palicnls with systemic sclerosis and pulmonary interstitial lesions were randomly divided into treatment group and control group,33 cases in treatment group and 32 cases in control group.2 groups were given conventional therapy,treatment group given Shenmaikaifei powders,control group given roxithromycin,acetylcysteine effervescent tablets.12 weeks for 1 course.After a course of treatment,observed the curative effect of the two groups,and detected 2 groups＇ before and after treatment＇s TCM syndromes score,6 minutes walk distance（6MWT）,HRCT were used to observe lung ground glass like lesions,pulmonary function[forced vital capacity（FVC）,the forced expiratory volume in one second（FEV_1）,FEV_1/FVC]improvement.Results Two groups had30 cases in each group completed the experiment,treatment group＇s total effective rate was 93.33%（28/30）,which was higher than that of the control group of 70.00%（21/30）,the difference was statistically significant（X^2=5.455,P〈0.05）.Compared with before treatment,after treatment in the two groups,TCM syndrome score,6MWT,HRCT lungs glass like lesions,pulmonary function improvement were improved（P〈0.01 or P〈0.05）,and in the treatment group,shortness ol breath,cough,TCM syndrome score,pulmonary lunction were better than those of the control group,the differences were statistically significant（P〈0.01 or P〈0.05）.Conclusion Efficacy of the Shenmaikaifei powders for treatment of pulmonary interstitial lesions in patients with systemic sclerosis is good.

关 键 词：系统性硬化症 肺间质病变 参麦开肺散 中西医结合疗法 临床疗效 

分 类 号：R259[医药卫生—中西医结合]